For the first time, scientists have reprogrammed cells from a 114-year-old woman into induced pluripotent stem cells (iPS cells), a move which they describe as a significant step toward understanding"the underlying mechanisms of extreme longevity and disease resistance."

iPS cells are adult cells that have been genetically reprogrammed into an embryonic stem cell-like state and are able to give rise to any of the specialized cell types of the body, whether its neurons, blood cells, or heart cells.

Until this new project, researchers werent even certain whether they could create viable iPS cellsfrom someone so elderly, let alone a supercentenarian. Now they have shown it's possible to effectively make these aged cells resemble young pluripotent cells, the researchers believe they might have made a step towards the reversal of cellular aging.

"We set out to answer a big question: Can you reprogram cells this old?" Evan Snyder, stem cell researcher at Sanford Burnham Prebys Medical Discovery Institute in California, said in a statement.

"Now we have shown it can be done, and we have a valuable tool for finding the genes and other factors that slow down the aging process."

Reporting in the journal Biochemical and Biophysical Research Communications, researchers harnessed iPS cells from the blood cells of a 114-year-old woman, a healthy 43-year-old person, and an 8-year-old child with a rare genetic condition characterized by the rapid aging in childhood. These iPS cells were then turned into mesenchymal stem cells, cells that help maintain and repair the body's structural tissues differentiating into bone, cartilage, muscle, or fat cells.

Remarkably, the cells produced from the supercentenarian transformed just as easily as the others. They also noted the supercentenarian-derived stem cells appeared to have reset their telomeres.

Telomeresarethe protective caps on the end of a chromosome. Since they shorten each time a cell copies itself, they also get shorter as we age and eventually stop functioning properly. Thispersistent shortening allows researchers to use telomeres as a kind of aging clock in every cell.Interestingly, the stem cells from the supercentenarian showed no indication of this aging. They had effectively reset the clock on the cells from114 years to zero.

To dive deeper into this discovery, the researchers hope to compare body cells derived from the healthy iPSCs and supercentenarian iPSCs. The researchers could also start to use the supercentenarian cells to understand why certain people have such long lives compared to others.

Why do supercentenarians age so slowly? We are now set to answer that question in a way no one has been able to before, said Snyder.

Read more from the original source:
Scientists Have 'Reset' The Cellular Age Of Cells Taken From A 114-Year-Old Woman - IFLScience

New York, United States, March 20, 2020 (GLOBE NEWSWIRE) -- The global recombinant cell culture supplements market, valued at US$ 320 Mn by the end of 2018, will grow at a steady rate from 2029-2029. The market players are investing in research and development activities to create new vaccines. They are targeting developing nations such as India and China for the same to benefit from their favorable government policies regarding foreign investments. Manufacturers are enhancing their presence across different distribution networks to market their products.

Recombinant Cell Culture Supplements Market: Key Takeaways

Request for sample Report: https://www.persistencemarketresearch.com/samples/31310

Recombinant Cell Culture Supplements Market: Key Growth Drivers

Recombinant Cell Culture Supplements Market: Key Restraints

The complete recombinant cell culture supplements market report with detailed market segmentation, 200 illustrative figures, and 63 data tables spread across 306 pages onhttps://www.persistencemarketresearch.com/methodology/31310

Recombinant Cell Culture Supplements Market: Competition LandscapeThe competition landscape is highly intense where every player is expanding its product portfolio to stay at the forefront in the market. established players are acquiring regional players to strengthen their regional footprint. For instance, Thermo Fisher Scientific acquired the bio-processing business of Becton Dickinson to expand its product portfolio.

Get Persistence Market Researchs Detailed Coverage OnCell Culture Media Market: Get intensive information on the global cell culture media market with vital updates on market growth drivers, changing market dynamics, existing market challenges, government policies and laws, segmental market forecast and key market strategies prominent players.

Human Platelet Lysate Market: PMRs study on the global human platelet lysate market provides an exhaustive analysis of the market set for steady during 2019-2029. The study also elaborates on a detailed evaluation of key forces influencing growth in the market, major revenue strategies and key market players with their winning market strategies.

Autogenous Vaccines Market: Get vital information on the global autogenous vaccines market with segment-based analysis, major market statistics, and key growth factors, prominent market players and key marketing strategies adopted by them for a period under projection.

Gain access to Market Ngage, an AI-powered, real-time business intelligence platform that goes beyond the conventional research solutions to solve the complex strategy challenges that organizations face today.

About the ReportPersistence Market Research's market research study on the recombinant cell culture supplements market contains a global analysis of the market through20142018and provides growth assessment for20192029. The study offers insightful details of the hydrogen market through four major segments delivery mode, end-use, production method, and region.

About Persistence Market Research

Persistence Market Research (PMR) is an innovative and specialized supplier ofmarket intelligence reportsandconsulting services. Prompt delivery, in-depth research, and high quality are the sacrosanct principles of PMR. The companys research capabilities cover 5 continents, 1500+ reports, and 8 next-gen vertical expertise that have been catering to research demands of 5000+ clients.

Contact:

Rajendra Singh

Persistence Market Research

U.S. Sales Office:

305 Broadway, 7th Floor

New York City, NY 10007

+1-646-568-7751

United States

USA - Canada Toll-Free: 800-961-0353

For Sales Enquiries: sales@persistencemarketresearch.com

For Media Enquiries: media@persistencemarketresearch.com

Research Report: https://www.persistencemarketresearch.com/market-research/recombinant-cell-culture-supplements-market.asp

Press Release Source: https://www.persistencemarketresearch.com/mediarelease/recombinant-cell-culture-supplements-market.asp

See original here:
Recombinant Cell Culture Supplements Receive a Boost from Stem Cell Research Ventures; Demand for Novel Vaccines to Act as a Growth Lever, Says PMR -...

GOLDEN, CO / ACCESSWIRE / March 26, 2020 / Vitro Diagnostics, Inc. (VODG), dba Vitro Biopharma, announced its 1st quarter ended January 31st, 2020 financial results of operations.

Vitro Diagnostics Inc. ("Vitro Biopharma") is pleased to announce a record 1st comparative quarter in Total Revenues. Vitro Biopharma recorded 1st quarter revenues of $225,921 vs $192,895 an increase of 17% over the same comparative quarter last year. In addition, Stem Cell treatments accounted for 74% of the revenues up from 71% of the revenues in the prior comparative quarter last year. Current quarter stem cell revenues were $167,750 for the 1st quarter ended January 31, 2020 vs $137,123 for the first quarter ended January 31, 2019.

The company's gross profit margins improved to 75% up from 73% in the comparative prior year's quarter. Gross margin improvement is in line with the strategic direction of the company to expand the market of its flagship product AlloRx Stem Cells. The company's clean-room lab expansion last year and expanded Stem Cell manufacturing using its patent-pending cell line, has increased efficiencies and lowered production costs.

Overall operating expenses increased in the quarter to $193,385 from $147,398 in the prior year's comparative quarter. The increase in expenses reflects additional investment as the Company expands its capability to service its strategic direction of offshore Stem Cell treatments while also expanding into US markets. The company expended additional resources on external consultants supporting our regulatory status in maintaining ISO9001 & ISO13485 certifications, expanding our efforts to approach US markets through FDA filings and advancement of existing patent filings.

The company's first quarter is its most seasonal quarter as the period between Thanksgiving and the New Year is slow for all the company's revenue lines of Nutra Vivo/STEMulize, AlloRx Stem Cells, private labeled InfiniVive-MD Stem Cell Serum and our core research products.

During the quarter the company achieved and pursed the following company objectives

During the quarter the company commenced a Series A Convertible Preferred Stock offering to accredited investors under the SEC Regulation D exemption. The preferred Stock is priced at $25 per share which is convertible at $0.25 cents per share for a total of 100 shares. The minimum investment is $50,000 per unit. The company sold $450,000 of the Series A Convertible Preferred Stock during the quarter. The company has additional interest in the offering and subsequent to the quarter has sold an additional $50,000 unit for a total to date of $500,000. The company has additional interested parties for approximately $200,000. The offering is for a total of $1,000,000.

Our partnership with DVC. Stem in the Cayman Islands continued to advance through treatment of new & previous patients. This IRB-approved protocol targets patients with inflammatory conditions including multiple sclerosis, systemic inflammation and new indications including Chrohn's disease, Alzheimer's disease and COPD. To date we have treated 60 patients including repeat treatments. There have been no serious adverse events and we continue to gain evidence of efficacy. One of the initial MS patients has now received a second transplant of our AlloRx Stem Cells and he has reported significant therapeutic benefits of both the initial and subsequent therapy. He had received an earlier transplant of adipose-derived MSCs that was effective, but the improvement lasted 3 months while AlloRx Stem Cell therapy lasted 18 months. We had predicted such a clinical outcome based on significantly higher potency of umbilical cord MSCS compared to those derived from adipose tissue or bone marrow. The Chrohn's disease patient showed significant improvement as did both the AD & COPD patients.

The strategic development of our stem cell therapies involves pursuit of both offshore and domestic markets. The partnership with DVC Stem, our IRB-approved trial in the Bahamas together with other strategic opportunities represent offshore operations & prospects. During Q1 2020, we initiated expansion into US therapeutic markets through development of an Investigational New Drug (IND) application for submission to FDA. Once approved, an IND allows the conduct of clinical trials for specific medical conditions in the US.

Story continues

Given the current COVID-19 pandemic, our initial IND application is for use of AlloRx Stem Cells in treatment of Coronavirus infections. This is supported by clinical studies showing that 17 critically ill patients responded favorably to IV infusion of umbilical cord-derived MSCs. All patients were receiving assisted ventilation but 3 days following stem cell therapy, were removed from ventilators and subsequently discharged from the hospital. We are pursuing discussions with FDA to establish the appropriate regulatory pathway and expedited review options given the current emergency circumstances. (See Subsequent Events, below, for additional discussion of our COVID-19 response.) Once our initial IND is in place, we have plans for additional INDs for stem cell therapy of musculoskeletal conditions and Alzheimer's disease.

We have received an initial order of AlloRx Stem Cells for testing purposes by PR Medica located in Cabo San Lucas. Given successful test results, we anticipate subsequent new revenue generation from this customer.

Vitro Biopharma's cosmetic topical stem cell serum is being distributed by InfiniVive MD into cosmetic clinics that are providing the topical treatment as a beautification product. To date the company's product is being offered in 10 cosmetic clinics.

Our partner, Dr Jack Zamora, MD was a keynote speaker at a master session at the American Academy of Cosmetic Surgery annual meeting in late February. The topic of his presentation was "Topical Stem Cells, Exosomes and Conditioned Media Serums in Aesthetics." This was the official launch of the InfiniVive-MD platform including: Dailey Serum, Stem Cell Serum 2.0 & Exosomes within the product line. Vitro Biopharma will manufacture & private label these new products for distribution in the US. We anticipate InfiniVive MD growth, development and revenues to mirror the development of Apyx subdermal plasma skin tightening as a cosmetic treatment and technique that has gone global.

http://www.jackzamoramd.com http://www.infinivivemd.com

Our core research product sales continued to expand in Q1 2020. Our facility expansion continued with addition of manufacturing capacity and development of plans to add operational facility to increase outputs further by 100% or more. We were also in discussions with the USPTO regarding our pending patents for our novel stem cell therapy and stem cell activation technology. We continue to work closely with our examiner and have established communication channels to facilitate awards of these patents.

The COVD-19 pandemic is a significant obstacle for all business. However, Vitro Biopharma is uniquely positioned since we have a potential effective therapy. This is based on 3 independent reports showing efficacy of stem cell therapy in 17 COVID-19 patients. All were treated with IV umbilical cord MSCs comparable to AlloRx Stem Cells and all 17 required respiratory assistance but within 3-4 days of treatment, were able to breath without ventilators and were discharged within 14 days. https://www.scmp.com/news/china/society/article/3053080/coronavirus-critically-ill-chinese-patient-saved-stem-cell On the contrary, untreated patients on ventilators have death rates of 50% or more. We have received a formal request to supply AlloRx Stem Cells for compassionate use from a major university medical center and several other potential clinical partners have also expressed interest in using our cells to treat COVID-19 patients. We are presently working with the FDA to gain authority to begin clinical testing in the US. We are currently assessing the overall financial impact of the COVID-19 pandemic on our business, but this depends on overall control of the pandemic. There have been no staff layoffs and our workers are considered essential since we conduct essential research to the COVID-19 response.

Dr. Jim Musick, CEO of Vitro Biopharma, said, "We are very pleased with the increased revenue growth during our first quarter 2020 compared to the prior year However all our resources are currently focused on the emergency response to the COVID-19 pandemic and increasing our inventory of AlloRx to satisfy anticipated emergency demand to treat critically ill COVID-19 patients." The Company is working to get expedited clinical trial approvals to sell our AlloRx Stem Cells to hospitals coping with the pandemic. Vitro is pleased to have recently been recognized by Bioinformant as "a Company Tracking the Coronavirus". https://bioinformant.com/product/coronavirus-covid-19-report/ We anticipate clinical progress in the effectiveness of our stem cell therapies while expecting to see a reduction in our offshore and cosmetic revenues for the next quarter or two. The company is in a good cash position to weather this storm and simultaneously advance its AlloRx stem cell therapies into clinical trials.

In summary, Vitro Biopharma is advancing as a key player in regenerative medicine with 10- years' experience in the development and commercialization of stem cell products for research, recognized by a Best in Practice Technology Innovation Leadership award for Stem Cell Tools and Technology and a growing track record of successful translation to therapy. We are leveraging our proprietary technology platform to the establishment of international Stem Cell Centers of Excellence and regulatory approvals in the US and worldwide.

Sincerely yours,

James R. Musick, PhD.President, CEO & Chairman of the Boardwww.vitrobiopharma.com

Forward-Looking Statements

Statements herein regarding financial performance have not yet been reported to the SEC nor reviewed by the Company's auditors. Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain "forward-looking statements". Such forward looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

Dr. James MusickChief Executive OfficerVitro BioPharma(303) 999-2130 Ext. 3E-mail: jim@vitrobiopharma.comwww.vitrobiopharma.com

The company provides its financial information for investor purposes only, the results published are not audited or necessarily SEC or GAAP compliant

The company provides its financial information for investor purposes only, the results published are not audited or necessarily SEC or GAAP compliant

The company provides its financial information for investor purposes only, the results published are not audited or necessarily SEC or GAAP compliant.

The company provides its financial information for investor purposes only, the results published are not audited or necessarily SEC or GAAP compliant.

SOURCE: Vitro Diagnostics, Inc.

View source version on accesswire.com: https://www.accesswire.com/582759/Vitro-Biopharma-First-Quarter-ended-January-31-2020-Financial-Results-of-Operations

Read more:
Vitro Biopharma First Quarter ended January 31, 2020 Financial Results of Operations - Yahoo Finance

Washington University School of Medicinein St. Louis released a newstudyabout the effectiveness of immunotherapy based on the age of the cells used. The study, published in the journalDevelopmental Cell,showed that these natural killer cells seem to be more effective when they are young. Natural killer (NK) cells, as they're called, are used in immunotherapy to treat cancer using the body's immune cells or immune cells from a matched donor.

"We are trying to improve the effectiveness of immunotherapy for more patients," said senior author Christopher M. Sturgeon, Ph.D., an assistant professor of medicine.

Typically, NK cells used in investigational immunotherapy are adult and come from the patient or donor bone marrow. While these therapies can work, they don't work for everyone.

In contrast, young NK cells do not use the patient's cell or donor cells. These early NK cells, typically formed in the yolk sac in the early embryo, are instead able to be created with human pluripotent stem cells. They can be manufactured quickly by most academic medical centers, thus eliminating the time it takes to process patient's or donor's cells for typical NK cell therapy.

"This special source of natural killer cells has the potential to fill some of the gaps remaining with adult NK cell therapy. There is early evidence that they are more consistent in their effectiveness, and we would not need to process cells from a donor or the patient. They could be manufactured from existing cell supplies following the strict federal guidelines for good manufacturing practices. The characteristics of these cells let us envision a supply of them ready to pull off the shelf whenever a patient needs them," Sturgeon said.

Instudieswith mice using the lab-developed human pluripotent stem cells to create early NK cells, researchers found positive results. These cells were significantly better at degranulation than adult NK cells. Even cells from umbilical cord blood did not respond as well as the early NK cells. Additionally, early NK cells are a particular type of short-lived immune cell, meaning that even if the cells cause harm, they aren't in the body for very long. However, NK cells, in general, do not attack the body's healthy tissues significantly, unlike many T cell therapies.

"Based on their unique behavior alone, there is one small clinical trial of these cells that is ongoing. Now that we know how to manufacture them and how they work, it opens the door for more trials and for improving upon their function, " Sturgeon said.

More research will need to be put into understanding why these special cells only show up in the early embryo and where they go after.

The origin and why they work so well is still a complete mystery.

"We can only speculate at this point, but it's possible that during early embryonic development, when there is so much rapid cell division, these cells are there as a surveillance mechanism to protect against pediatric cancers or infection," he said.

In addition to the early NK cells, pluripotent stem cells also have the potential to bring about many other different cell types, creating more possibilities.

Here is the original post:
Study Shows Development of Young Cells Could be New Option in Cancer Care - BioSpace

(The Center Square) California is under a shelter-in-place order due to the coronavirus pandemic, but several ballot initiative campaigns are in the final days or weeks of their signature drives. As of March 23, four citizen-initiated measures have qualified to appear on the ballot in November. An additional nine ballot initiatives could receive enough signatures to appear on the ballot.

The deadline for signature verification is June 25, 2020. However, the process of verifying signatures can take multiple months. Secretary of State Alex Padilla (D) recommends that campaigns file signatures no later than April 21. Campaigns that file signatures after the deadline can still have their proposals appear on the ballot for November 8, 2022.

Gov. Gavin Newsom (D) has directed residents to remain at home, except as needed for food, medicine, and other services deemed essential, due to the pandemic. The California Department of Health has advised that non-essential gatherings be postponed or canceled, and the CDC is recommending that people maintain distance between each other.

Jamie Court, president of Consumer Watchdog, stated, We were getting 70,000 signatures a week until a couple of weeks ago, when it almost stopped. According to Fred Kimball, owner of the signature-gathering firm Kimball Petition Management, Were all flying by the seat of our pants. No one has ever seen this.

Campaigns behind the following nine citizen-initiated measures are seeking a place for their proposals on the general election ballot. Coronavirus, however, could have the effect of limiting the number of signatures that an individual petitioner can collect, especially for campaigns that didnt launch until January 2020.

Property Tax Transfers and Exemptions Initiative (#19-0003): The campaign Homeownership for Families and Tax Savings for Seniors filed 1.43 million signatures on March 4. At least 997,139 signatures need to be valid. The ballot measure would change how tax assessments are transferred between properties for eligible homebuyers and address resetting tax assessments to fair market value on inherited properties and when corporations and other entities acquire control of properties. Homeownership for Families and Tax Savings for Seniors, which is associated with the California Association of Realtors, has raised $12.08 million.

Tax on Commercial and Industrial Properties for Education and Local Government Funding Initiative (#19-0008): An earlier version of the citizen-initiated measure has qualified for the ballot, but the campaign Schools and Communities First is seeking to replace the initiative with an amended version. The campaign needs to file at least 997,139 valid signatures. Schools and Communities First has raised $17.13 million. Both versions of the ballot initiative would amend the state constitution to require commercial and industrial properties, except those zoned as commercial agriculture, to be taxed based on their market value.

Consumer Personal Information Law and Agency Initiative (#19-0021): The ballot initiative seeks to expand the provisions of the California Consumer Privacy Act (CCPA), which was passed in 2018. The campaign Californians for Consumer Privacy raised $3.42 million for this years effort. Robin Swanson, a consultant for the campaign, said, Were in pretty good shape with the numbers that we have, but are adhering to public health requirements and putting public safety first. Like most ballot measure campaigns out there, wed always love more signatures, but were dealing with a stark new reality while the state is on lockdown. At least 623,212 valid signatures need to be filed for the ballot measure.

Stem Cell Research Institute Bond Initiative (#19-0022): Californians for Stem Cell Research, Treatments, and Cures is backing a ballot initiative to issue $5.5 billion in general obligation bonds for the state's stem cell research institute. Spokesperson Sarah Melbostad said the campaigns signature drive has been suspended due to the coronavirus pandemic. "In keeping with the governors statewide order for non-essential businesses to close and residents to remain at home, weve suspended all signature gathering for the time being. ... Were confident that we still have time to qualify and plan to proceed accordingly, said Melbostad. Proponents have raised $5.28 million. The campaign needs to collect at least 623,212 valid signatures.

Dialysis Clinic Requirements and Consent to Close Initiative (#19-0025): Californians for Kidney Dialysis Patient Protection, which backed a defeated dialysis-related initiative in 2018, has raised $5.38 million for the new effort. The campaign needs at least 623,212 valid signatures.

App-Based Drivers Regulations Initiative (#19-0026): With $110.58 million, Protect App-Based Drivers and Services has collected over 1 million signatures, of which 623,212 need to be valid. The campaign has the support of Uber, Lyft, Doordash, Instacart, and Postmates. The ballot measure would consider app-based drivers to be independent contractors and enact several wage and labor policies that would affect app-based drivers and companies. Spokesperson Stacy Wells said, We were really lucky. We got our signatures in fast and were able to get off the streets in seven weeks.

Packaging Waste Reduction Regulations Initiative (#19-0028): The ballot measure would require CalRecycle, in consultation with other agencies, to adopt regulations that reduce the use of product packaging, single-use packaging, and single-use dishes and utensils. The campaign Clean Coasts, Clean Water, Clean Streets has raised $3.26 million. At least 623,212 valid signatures need to be collected.

Legalize Sports Betting on American Indian Lands Initiative (#19-0029): The Coalition to Authorize Regulated Sports Wagering, with the support of several tribal governments, has raised $7.5 million for a ballot measure to legalize sports betting at American Indian gaming casinos and licensed racetracks. The effort to collect 997,139 valid signatures began on January 21, 2020. We are at nearly 1 million signatures and were on a trajectory to reach our goal well ahead of the deadline before the unprecedented orders around COVID-19, said Jacob Mejia, a spokesperson for the campaign. He added, The health and well-being of Californians is foremost. Thus, paid signature-gathering efforts have paused for the time being.

More here:
California ballot initiative campaigns are in the final weeks of their signature drives and face the effects of coronavirus - The Center Square

The positioning of the Global Cell Expansion Market vendors in FPNV Positioning Matrix are determined by Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinders, N: Niche, and V: Vital).

New York, March 25, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Cell Expansion Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025" - https://www.reportlinker.com/p05872140/?utm_source=GNW

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Cell Expansion Market including are Beckman Coulter Inc., Becton, Dickinson and Company, Merck KGaA, Terumo BCT, Thermo Fisher Scientific, Inc., Corning Incorporated, GE Healthcare, Lonza Group LTD., Miltenyi Biotec, Promocell GmbH, Sartorius AG, Stemcell Technologies, Inc., and Takara Bio Inc..

On the basis of Product, the Global Cell Expansion Market is studied across Consumables and Instruments.

On the basis of Cell Type, the Global Cell Expansion Market is studied across Animal Cells and Human Cells.

On the basis of Application, the Global Cell Expansion Market is studied across Cancer and Cell-Based Research and Regenerative Medicine and Stem Cell Research.

On the basis of End User, the Global Cell Expansion Market is studied across Biotechnology & Biopharmaceutical Companies, Cell Banks, and Research Institutes.

For the detailed coverage of the study, the market has been geographically divided into the Americas, Asia-Pacific, and Europe, Middle East & Africa. The report provides details of qualitative and quantitative insights about the major countries in the region and taps the major regional developments in detail.

In the report, we have covered two proprietary models, the FPNV Positioning Matrix and Competitive Strategic Window. The FPNV Positioning Matrix analyses the competitive market place for the players in terms of product satisfaction and business strategy they adopt to sustain in the market. The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisitions strategies, geography expansion, research & development, new product introduction strategies to execute further business expansion and growth.

Research Methodology:Our market forecasting is based on a market model derived from market connectivity, dynamics, and identified influential factors around which assumptions about the market are made. These assumptions are enlightened by fact-bases, put by primary and secondary research instruments, regressive analysis and an extensive connect with industry people. Market forecasting derived from in-depth understanding attained from future market spending patterns provides quantified insight to support your decision-making process. The interview is recorded, and the information gathered in put on the drawing board with the information collected through secondary research.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players in the Global Cell Expansion Market 2. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments in the Global Cell Expansion Market 3. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets for the Global Cell Expansion Market 4. Market Diversification: Provides detailed information about new products launches, untapped geographies, recent developments, and investments in the Global Cell Expansion Market 5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the Global Cell Expansion Market

The report answers questions such as:1. What is the market size of Cell Expansion market in the Global?2. What are the factors that affect the growth in the Global Cell Expansion Market over the forecast period?3. What is the competitive position in the Global Cell Expansion Market?4. Which are the best product areas to be invested in over the forecast period in the Global Cell Expansion Market?5. What are the opportunities in the Global Cell Expansion Market?6. What are the modes of entering the Global Cell Expansion Market?Read the full report: https://www.reportlinker.com/p05872140/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Here is the original post:
The Global Cell Expansion Market is expected to grow from USD 11,923.12 Million in 2018 to USD 30,023.12 Million by the end of 2025 at a Compound...

The global cell isolation market is projected to generate $12.6 billion revenue by 2023 by P&S Intelligence.

The primary factors propelling the cell isolation market to prosperity are the increasing demand for biopharmaceuticals, funding by the government for cell-based research, and rising number of studies on personalized medicine. The market, which generated a revenue of $4.6 billion in 2017, is predicted to progress at an 18.8% CAGR during 20182023 (forecast period), to ultimately value $12.6 billion by 2023.

For diagnostic testing and disease prognosis, cells of various types are identified and extracted from the body.

Download sample copy of this report@ http://www.psmarketresearch.com/market-ort-sample

Based on type, the cell isolation market is bifurcated into animal and human cells, of which animal cells held the larger revenue share in 2017. Animal cells, primarily those derived from mice, are heavily used in drug development to study the preliminary efficacy, toxicity, and pharmacokinetics of new drug molecules.

During the forecast period, faster growth would be witnessed by the human cell bifurcation, at a CAGR of 19.9%, owing to the rapid enhancements in the stem cell technology, which is being utilized to treat numerous diseases.

The use of biopharmaceuticals for the early detection of various cancers is leading to the cell isolation market growth. Such molecules, especially those isolated from proteins, are also being rapidly utilized in the treatment of melanoma and chronic myelogenous leukemia.

The antigens and abnormal pathways associated with these conditions are now being targeted with mAbs. With the increasing awareness of people about the advantages of such products in the treatment of cancer, their usage is rising, which, in turn, is leading to the surging adoption of cell isolation for their production.

Inquiry at@ http://www.psmarketresearch.com/send-enion-market

In 2017, North America was the largest cell isolation market across the world, with an around 38.0% revenue share. This was because a large number of biotechnology and pharmaceutical organizations, academic institutions, and research laboratories, which use the technique, are present in the region.

During the forecast period, Asia-Pacific (APAC) is expected to observe the fastest growth, at a 22.1% CAGR, due to the rising focus on applied and basic medical research here, especially in India and China, where a number of institutes dedicated to cell-based research have been founded.

Thus, with the surging requirement for biopharmaceuticals, especially those needed to treat cancer, the usage of cell isolation would continue to increase around the globe.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Originally posted here:
Cell Isolation Market overview, share, key players and forecast report by 2023 edited by leading research firm - WhaTech Technology and Markets News

New York, March 25, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Cell Isolation/Cell Separation Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025" - https://www.reportlinker.com/p05872137/?utm_source=GNW

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Cell Isolation/Cell Separation Market including are Beckman Coulter Inc. (Subsidiary of Danaher Corporation), Becton, Dickinson and Company, Merck KGaA, Terumo Bct, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., GE Healthcare, Miltenyi Biotec, Pluriselect Life Science Ug (Haftungsbeschrnkt) & Co. Kg, and Stemcell Technologies, Inc..

On the basis of Product, the Global Cell Isolation/Cell Separation Market is studied across Consumables and Instruments.

On the basis of Cell Type, the Global Cell Isolation/Cell Separation Market is studied across Animal Cells and Human Cells.

On the basis of Cell Source, the Global Cell Isolation/Cell Separation Market is studied across Adipose Tissue, Bone Marrow, and Cord Blood/Embryonic Stem Cells.

On the basis of Technique, the Global Cell Isolation/Cell Separation Market is studied across Centrifugation-Based Cell Isolation, Filtration-Based Cell Isolation, and Surface Marker-Based Cell Isolation.

On the basis of Application, the Global Cell Isolation/Cell Separation Market is studied across Biomolecule Isolation, Cancer Research, In Vitro Diagnostics, Stem Cell Research, and Tissue Regeneration & Regenerative Medicine.

On the basis of End User, the Global Cell Isolation/Cell Separation Market is studied across Biotechnology & Biopharmaceutical Companies, Hospitals & Diagnostic Laboratories, and Research Laboratories & Institutes.

For the detailed coverage of the study, the market has been geographically divided into the Americas, Asia-Pacific, and Europe, Middle East & Africa. The report provides details of qualitative and quantitative insights about the major countries in the region and taps the major regional developments in detail.

In the report, we have covered two proprietary models, the FPNV Positioning Matrix and Competitive Strategic Window. The FPNV Positioning Matrix analyses the competitive market place for the players in terms of product satisfaction and business strategy they adopt to sustain in the market. The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisitions strategies, geography expansion, research & development, new product introduction strategies to execute further business expansion and growth.

Research Methodology:Our market forecasting is based on a market model derived from market connectivity, dynamics, and identified influential factors around which assumptions about the market are made. These assumptions are enlightened by fact-bases, put by primary and secondary research instruments, regressive analysis and an extensive connect with industry people. Market forecasting derived from in-depth understanding attained from future market spending patterns provides quantified insight to support your decision-making process. The interview is recorded, and the information gathered in put on the drawing board with the information collected through secondary research.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players in the Global Cell Isolation/Cell Separation Market 2. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments in the Global Cell Isolation/Cell Separation Market 3. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets for the Global Cell Isolation/Cell Separation Market 4. Market Diversification: Provides detailed information about new products launches, untapped geographies, recent developments, and investments in the Global Cell Isolation/Cell Separation Market 5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the Global Cell Isolation/Cell Separation Market

The report answers questions such as:1. What is the market size of Cell Isolation/Cell Separation market in the Global?2. What are the factors that affect the growth in the Global Cell Isolation/Cell Separation Market over the forecast period?3. What is the competitive position in the Global Cell Isolation/Cell Separation Market?4. Which are the best product areas to be invested in over the forecast period in the Global Cell Isolation/Cell Separation Market?5. What are the opportunities in the Global Cell Isolation/Cell Separation Market?6. What are the modes of entering the Global Cell Isolation/Cell Separation Market?Read the full report: https://www.reportlinker.com/p05872137/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

See the rest here:
The Global Cell Isolation/Cell Separation Market is expected to grow from USD 5,721.23 Million in 2018 to USD 15,089.25 Million by the end of 2025 at...

The positioning of the Global Cell Culture Market vendors in FPNV Positioning Matrix are determined by Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinders, N: Niche, and V: Vital).

New York, March 25, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Cell Culture Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025" - https://www.reportlinker.com/p05872141/?utm_source=GNW

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Cell Culture Market including are Becton, Dickinson and Company, Cellgenix, Corning, Danaher, Eppendorf, Fujifilm Irvine Scientific, GE Healthcare, Hi-Media Laboratories, Invivogen, Lonza Group AG, Merck KGaA, Miltenyi Biotec, Promocell, and Sartorius AG.

On the basis of Product, the Global Cell Culture Market is studied across Consumables and Equipment.

On the basis of Application , the Global Cell Culture Market is studied across Biopharmaceutical Production, Diagnostics, Drug Screening and Development, Stem Cell Research, and Tissue Engineering & Regenerative Medicine.

On the basis of End User , the Global Cell Culture Market is studied across Cell Banks, Hospitals and Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, and Research Institutes.

For the detailed coverage of the study, the market has been geographically divided into the Americas, Asia-Pacific, and Europe, Middle East & Africa. The report provides details of qualitative and quantitative insights about the major countries in the region and taps the major regional developments in detail.

In the report, we have covered two proprietary models, the FPNV Positioning Matrix and Competitive Strategic Window. The FPNV Positioning Matrix analyses the competitive market place for the players in terms of product satisfaction and business strategy they adopt to sustain in the market. The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisitions strategies, geography expansion, research & development, new product introduction strategies to execute further business expansion and growth.

Research Methodology:Our market forecasting is based on a market model derived from market connectivity, dynamics, and identified influential factors around which assumptions about the market are made. These assumptions are enlightened by fact-bases, put by primary and secondary research instruments, regressive analysis and an extensive connect with industry people. Market forecasting derived from in-depth understanding attained from future market spending patterns provides quantified insight to support your decision-making process. The interview is recorded, and the information gathered in put on the drawing board with the information collected through secondary research.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players in the Global Cell Culture Market 2. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments in the Global Cell Culture Market 3. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets for the Global Cell Culture Market 4. Market Diversification: Provides detailed information about new products launches, untapped geographies, recent developments, and investments in the Global Cell Culture Market 5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the Global Cell Culture Market

The report answers questions such as:1. What is the market size of Cell Culture market in the Global?2. What are the factors that affect the growth in the Global Cell Culture Market over the forecast period?3. What is the competitive position in the Global Cell Culture Market?4. Which are the best product areas to be invested in over the forecast period in the Global Cell Culture Market?5. What are the opportunities in the Global Cell Culture Market?6. What are the modes of entering the Global Cell Culture Market?Read the full report: https://www.reportlinker.com/p05872141/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Original post:
The Global Cell Culture Market is expected to grow from USD 14,923.23 Million in 2018 to USD 35,236.23 Million by the end of 2025 at a Compound Annual...

When Phil Huntley started experiencing cold and flu-like symptoms just weeks after his wedding, he initially thought very little of it.

But after visiting his GP and seeing an out-of-hours doctor, his condition deteriorated to such an extent that he collapsed at home.

Tests in hospital confirmed that not only did the 38-year-old have pneumonia and sepsis, but also a rare form of leukaemia which has now spread to his skin and central nervous system.

He has now been told he may have just months left to live after a stem cell transplant failed.

The most recent news has devastated us, but we remain hopeful that against all odds all will be well, said his wife Sian Huntley, 50.

We are determined to live our best lives, make every day count and be grateful for everything.

We are doing our best to make sure the absolute fear that we feel doesn't take over, and instead we breathe and live each moment with joy and gratitude.

Phil, who married Sian in December 2018, said he started suffering with severe night sweats in January 2019 before he became increasingly unwell.

I was dosing myself up on flu relief and still going to work every day. I carried on like that for a few weeks, recalled Phil, a former employee with the National Trust.

Eventually I went to my GP as I knew something wasn't right, but they just said 'something was going around' at the moment and told me to come back in a few days for a blood test if things didn't improve.

After seeing an out-of-hours GP who gave him antibiotics for a suspected chest infection, his condition deteriorated further.

One day it took until 2pm to get out of bed. I managed to find the strength to have a shower. At one point I lost my footing, but moments later everything just went black.

I woke up in Sian's arms who was on the phone to the ambulance.

In A&E at Withybush Hospital in Haverfordwest, blood tests revealed that Phil had pneumonia and sepsis, a condition which causes the body's immune to go into overdrive and start attacking healthy tissue and organs.

It was also discovered that the Solva resident had leukaemia and would need to be transferred to the University Hospital of Wales (UHW) in Cardiff.

Leukaemia was the last thing that crossed my mind, said Phil.

I think the gravity of the whole situation only hit me towards the end of my ambulance ride between Withybush and UHW.

I just felt shock - and such disbelief that I could have laughed. Between myself and Sian we have four children and all I could do is think of them.

While Phil recovered quickly from sepsis, he would need many gruelling rounds of chemotherapy to treat the leukaemia.

I was in UHW for two months to begin with, a week of which was in intensive care, Phil added.

That's all pretty much a blur, and for the first month I didn't leave my bed.

In the second month I had to learn to walk again. When I managed to get myself to the toilet for the first time on my own it was a little personal victory.

Sian added that their four children Dylan, nine; Ben, 10; Katie, 14; and Amy, 16, have all been brilliant while Phil has been unwell.

She said: They all help in any way they can. We know they are struggling and worrying about things. The two older girls have taken on some additional responsibility such as looking after Ben.

But emotionally it has really taken its toll.

Phil, who was later also found to have aspergillosis, a condition which causes major breathing problems, ended up contracting sepsis four times in total following every round of chemotherapy.

Every time he had chemotherapy we were on red alert and would need to take him to hospital, said Sian.

But the staff at Withybush Hospital were amazing and acted straight away to prevent Phil from going into septic shock.

Video Unavailable

Click to playTap to play

Play now

In November 2019, nurses informed Phil that a positive stem cell match had been found for him, giving him hope that he may be cured.

It was a 27-year-old guy from somewhere in Wales and the match was 100%, he said.

But by this point I'd developed leukaemia of the skin, which is only found in around 2% of leukaemia patients. The Cardiff team hadn't really dealt with it previously.

I was in isolation for four to six weeks in UHW for chemotherapy, then I went to Velindre for radiotherapy on my skin, and then I went back to UHW for the transplant to be carried out which was done through an IV drip into my arm.

While Phil started to see signs of improvement early on after the transplant, by mid February 2020 the legions that had vanished from his skin began to reappear.

It's been horrendous, said Sian. At times none of this has seemed real.

His condition is so rare that there is currently no research or medical trials taking place.

A GoFundMe page was set up for the family by close friend Jacqueline Roberts so they can enjoy the time they have left together by going on regular trips around Wales and the UK.

To donate, go to https://www.gofundme.com/f/phil-the-super-hero

But sadly, due to the outbreak of coronavirus and Phil being classified as an extremely at risk patient, he is unable to leave his Pembrokeshire home for at least the next three months.

Sian admitted that she was terrified of picking up the virus and passing it onto her severely unwell husband.

Sian said: We wanted to make some memories as a family, but we are obviously very mindful of the current situation.

We wanted to go to Cornwall as a family but that's obviously not happening now. We are very fortunate to live in a very beautiful part of Wales anyway.

Phil, who is now having monthly injections to slow down the progress of the leukaemia, said he is looking forward to spending some time at home with his family.

I've been either in the hospital or stuck in the house for quite some time now. I just feel sorry for the children as they cannot go anywhere, he said.

Visit link:
Dad told he has months left to live after stem cell transplant fails - Wales Online